PT  - JOURNAL ARTICLE
AU  - Wheless, Lee
AU  - Liao, Kai-Ping
AU  - Zheng, Siwei
AU  - Li, Yao
AU  - Yao, Lydia
AU  - Xu, Yaomin
AU  - Madden, Christopher
AU  - Ike, Jacqueline
AU  - Smith, Isabelle T
AU  - Mosley, Dominique
AU  - Grossarth, Sarah
AU  - Hartman, Rebecca I
AU  - Wilson, Otis
AU  - Hung, Adriana
AU  - Wehner, Mackenzie R
TI  - Toward personalized skin cancer care: multiple skin cancer development in five cohorts
AID  - 10.1101/2024.05.06.24306947
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.06.24306947
4099  - http://medrxiv.org/content/early/2024/05/07/2024.05.06.24306947.short
4100  - http://medrxiv.org/content/early/2024/05/07/2024.05.06.24306947.full
AB  - Importance Many patients will develop more than one skin cancer, however most research to date has examined only case status.Objective Describe the frequency and timing of the treatment of multiple skin cancers in individual patients over timeDesign Longitudinal claims and electronic health record-based cohort studySetting Vanderbilt University Medical Center database called the Synthetic Derivative, VA, Medicare, Optum Clinformatics® Data Mart Database, IBM MarketscanParticipants All patients with a Current Procedural Terminology code for the surgical management of a skin cancer in each of five cohorts.Exposures None.Main Outcomes and Measures The number of CPT codes for skin cancer treatment in each individual occurring on the same day as an ICD code for skin cancer over timeResults Our cohort included 5,508,374 patients and 13,102,123 total skin cancers treated.Conclusions and Relevance Nearly half of patients treated for skin cancer were treated for more than one skin cancer. Patients who have not developed a second skin cancer by 2 years after the first are unlikely to develop multiple skin cancers within the following 5 years. Better data formatting will allow for improved granularity in identifying individuals at high risk for multiple skin cancers and those unlikely to benefit from continued annual surveillance. Resource planning should take into account not just the number of skin cancer cases, but the individual burden of disease.Key points Question: How many skin cancer patients are treated for more than one skin cancer and how soon after the first skin cancer do they occur?Findings: 43% of patients were treated for more than one skin cancer, the majority of which occurred within two years after the initial skin cancer. Just 3% of patients were treated for 10 or more skin cancers, but these patients accounted for 22% of all of the skin cancer treatments in the cohort Meaning: Nearly half of all skin cancer patients were treated for multiple skin cancers, while those without a second skin cancer after two years were less likely to be treated for a subsequent skin cancer within the next five years.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Wheless is supported by VA CSR&D grant IK2 CX002452. Dr. Hartman is supported by VA CSR&D grant IK2 CX002531. Dr. Wehner is supported by NCI grant K08CA263298. This research was supported by Cancer Prevention and Research Institute of Texas RR190078 (MRW) and a grant from the University of Texas Rising STARs program (MRW), as well as, in part, by Cancer Center Support Grant P30 CA016672 to MD Anderson Cancer Center. MRW is a Cancer Prevention and Research Institute of Texas Scholar in Cancer Research. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The project described was supported by CTSA award No. UL1TR000445 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences, the National Institutes of Health, the Department of Veteran Affairs, or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the institutional review boards (IRB) of Vanderbilt University Medical Center (VUMC) (non-human subjects designation, IRB# 200335), Tennessee Valley Health System Veterans Administration Medical Center (exempt status, IRB# 1657284), and MD Anderson Cancer Center (IRB# 2019-0966).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData for each cohort are access-protected and cannot be shared externally in accordance with the authors' data use agreementsCPTcurrent procedural terminologyEHRelectronic health recordICDinternational classification of diseaseIRBInstitutional Review BoardVINCIVeteran’s Administration Informatics and Computing InfrastructureVUMCVanderbilt University Medical Center